MTMasanori Tokumoto

Masanori Tokumoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masanori Tokumoto has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prevalence of hyponatremia and associated factors in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry (FKR) study

    by Megumi Inoue, Kentaro Nakai, Shigeru Tanaka, Koji Mitsuiki, Masanori Tokumoto, Kazuhiko Tsuruya, Takanari Kitazono, Toshiaki Nakano

    Background Hyponatremia is a common and important electrolyte disorder. However, the prevalence and factors associated with hyponatremia in patients with chronic kidney disease (CKD) are unknown. Methods We studied the factors associated with hyponatremia (< 135 mEq/L) in CKD patients registered in the Fukuoka Kidney Disease Registry (FKR) study using a logistic regression model variable selected using the variable reduction method. Results We analyzed the baseline characteristics of 4367 participants with CKD (age, 64 ± 16 years; male, 56.1%). Hyponatremia was detected in 2.0% of the patients at baseline, and multivariate logistic analysis showed that the independent factors for hyponatremia were body mass index (odds ratio [OR] 0.91; 95% confidence interval [CI] 0.85–0.97), prescription of benzodiazepine (OR 2.31; 95% CI 1.39–3.86), blood hemoglobin level (OR 0.76; 95% CI 0.65–0.88), and serum C-reactive protein level (OR 1.27; 95% CI 1.04–1.54). Conclusion The cross-sectional analysis using baseline data from the FKR study revealed independent factors associated with hyponatremia in patients with decreased kidney function. Longitudinal analyses of the FKR cohort are needed to evaluate the effects of these factors on the prognosis of hyponatremia in patients with CKD.


  • Kidney Diseases

    by Masanori Tokumoto, Koichi Hayashi, Hiroshige Ohashi, Akira Sasaki

  • Open Access

    Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism

    by Masanori Tokumoto, Shin Tokunaga, Shinji Asada, Yuichi Endo, Noriaki Kurita, Masafumi Fukagawa, Tadao Akizawa

    The dosage of evocalcet required to control serum parathyroid hormone (PTH) levels varies among secondary hyperparathyroidism (SHPT) patients. This post hoc analysis evaluated the dose-dependent efficacy of evocalcet on serum intact PTH (iPTH) levels, corrected calcium (Ca) and phosphate (P) levels, and safety, in an evaluation period (week 28 to week 30) by stratifying the previous phase 3 data with the final evocalcet dosages (low 1–2 mg [131 patients], medium 3–4 mg [90 patients], high 5–8 mg [92 patients]), and identified pre-treatment patient characteristics predicting the use of higher final evocalcet dosages via univariate and multivariate logistic regression models. At the end of the study at week 30, the median serum iPTH level was higher and the achievement ratio for the target range of Japanese Society for Dialysis Therapy (60–240 pg/mL) was lower in the final high-dose subgroup (216 pg/mL and 58%, respectively) than in the other subgroups (low: 149 pg/mL and 79%; medium: 149 pg/mL and 73%, respectively). Among the three subgroups, the mean serum corrected Ca and P levels demonstrated similar trends, and similar ratio of patients achieved the target range (corrected Ca, 8.4–10 mg/dL; P, 3.5–6.0 mg/dL) from week 28 to week 30. No dose-dependent safety concerns were identified. Younger age, prior cinacalcet use, higher serum levels of iPTH and corrected Ca, procollagen type 1 N-terminal propeptide, intact fibroblast growth factor-23, and larger maximum parathyroid gland volume were significantly associated with final high-dose evocalcet (p < 0.05 in all cases). Patients requiring final high-dose evocalcet had pre-treatment characteristics indicating severe SHPT, leading to a lower final achievement rate for the target PTH levels of Japanese Society for Dialysis Therapy. Therefore, the early initiation of evocalcet treatment for SHPT is critical. Trial registration: This trial was registered as follows: ClinicalTrials.gov: NCT02549391 and JAPIC: JapicCTI-153013.


  • Open Access

    Malnutrition-Inflammation Complex Syndrome and Bone Fractures and Cardiovascular Disease Events in Patients Undergoing Hemodialysis: The Q-Cohort Study

    by Shunsuke Yamada, Hokuto Arase, Hisako Yoshida, Hiromasa Kitamura, Masanori Tokumoto, Masatomo Taniguchi, Hideki Hirakata, Kazuhiko Tsuruya, Toshiaki Nakano, Takanari Kitazono


  • Open Access

    Decreased expression of calcium-sensing receptor and parafibromin in secondary hyperparathyroidism with an abnormal whole PTH/intact PTH ratio

    by Shunsuke Yamada, Masanori Tokumoto, Masatomo Taniguchi, Hidehisa Kitada, Kazuhiko Tsuruya, Takanari Kitazono

    A 34-year-old female hemodialysis patient with an abnormal whole parathyroid hormone (PTH)/intact PTH ratio (ratio = 1.14) underwent parathyroidectomy for advanced secondary hyperparathyroidism. The abnormal PTH ratio indicated a relative increase in the serum N-terminus PTH, a new molecular form of PTH. The abnormal ratio normalized immediately after the largest parathyroid gland (PTG) was removed, proving the largest PTG as causative. An immunohistochemical analysis revealed extremely decreased expression of the calcium-sensing receptor and parafibromin in the largest PTG in comparison with the other PTGs. This case indicated the possible involvement of decreased calcium-sensing receptor and parafibromin signaling in the development of the abnormal PTH ratio.


  • Open Access

    Acute interstitial nephritis with immune complex deposition and MHC class II antigen presentation along the tubular basement membrane

    by Masanori Tokumoto, Kyoichi Fukuda, Michiya Shinozaki, Minoru Kashiwagi, Ritsuko Katafuchi, Tetsuhiko Yoshida, Taihei Yanagida, Hidetoshi Kanai, Hideki Hirakata, Kiyoshi Tamaki, et al.

    Renal tubulointerstitium has been recognized to be a common site of immune-complexes deposition leading to tissue destruction [1–3]. However, cases of interstitial nephritis in which interstitial immune complex deposition play a major role are not commonly reported [4–14]. Most reported cases have been finally diagnosed as either collagen disease or adenovirus-type 11 infection.